Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines reported third-quarter 2026 results and business updates, including two Phase 3 studies of GB-0895, oncology program progress, and collaborations with Zealand Pharma and Anthropic. The company reported $404.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
Why it matters — The update highlights advancement of clinical programs, collaboration economics, and the company’s reported cash position.